Nutex Health 2025 Q3 Earnings Record Net Income Surges 1451%

Nutex Health (NUTX) reported fiscal 2025 Q3 earnings on November 20, 2025, with revenue surging 239.9% to $267.80 million and net income turning positive at $96.80 million, reversing a $7.17 million loss in 2024 Q3. The results significantly exceeded expectations, driven by robust hospital division performance and arbitration success.

Revenue

The Hospital division led the growth with $260.24 million in revenue, while the Population health management division contributed $7.57 million. The Real estate division reported no revenue for the quarter. Total revenue of $267.80 million reflects a dramatic year-over-year increase, underscoring the company’s strategic focus on hospital operations and arbitration-driven collections.

Earnings/Net Income

Nutex Health returned to profitability with EPS of $8.27 in 2025 Q3, reversing a $1.72 loss in 2024 Q3. Net income surged 1451.0% to $96.80 million, marking a record high for fiscal Q3 and highlighting the company’s operational turnaround. The company’s ability to convert revenue growth into profitability underscores its strong financial positioning.

Post-Earnings Price Action Review

Recent performance highlights Nutex Health’s strong Q3 results, with revenue exceeding expectations and a significant impact from the No Surprises Act (NSA) independent dispute resolution process. Following the Q3 results announcement, the stock surged 20.97% in after-hours trading, reflecting investor confidence. Analysts at Benchmark reiterated a “Buy” rating with a $300 price target, aligning with the current trading price and suggesting potential for capital appreciation. While the 30-day holding period carries short-term risks, the company’s robust revenue growth of 239.9% in Q3 and positive market sentiment provide a solid foundation for sustained momentum. Investors should remain vigilant to evolving fundamentals or market conditions.

CEO Commentary

CEO Tom Vo and CFO Jon Bates emphasized the company’s “record year” with 225% revenue growth and $243.0 million Adjusted EBITDA, alongside a $166.0 million cash balance. Leadership highlighted a strong balance sheet, arbitration success (85% win rate), and operational execution as key drivers for future growth through existing operations and new facilities.

Guidance

Management outlined a growth strategy focused on arbitration processes, mature hospital performance (200% YoY revenue growth in nine months), and leveraging a strong balance sheet for expansion. While no explicit numerical guidance was provided, the company emphasized risks related to regulatory changes and capital needs. A conference call on December 2, 2025, will discuss restated 2024 results and Q1-Q3 2025 performance.

Additional News

Nutex Health faces a securities class action lawsuit filed in the Southern District of Texas, alleging misstatements in a short seller report. The company also announced key leadership changes, including Wesley Bamburg as COO, bringing experience from HCA Houston Healthcare, and Michael L. Reed as lead independent director to strengthen corporate governance. Separately, Newtek Health reported a 220% revenue increase for Q2 2025, underscoring sector-wide growth amid rising costs.